Graybug Vision is a clinical stage pharmaceutical company developing novel products for the treatment of ocular diseases. The company's proprietary injectable products are designed to enable less frequent administration to reduce the burden of treatment for patients and their physicians. The company's lead clinical-stage injectable product, GB-102, has the potential to achieve 6-month dosing in the treatment of retinal diseases. GB-401 has the potential to achieve 4 to 6-month dosing in the treatment of elevated IOP associated with POAG.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/20/19 | $80,000,000 | Series C |
CBC Group Deerfield Management Company, L.P. Hatteras Venture Partners OrbiMed Advisors | undisclosed |
